MKMara Koelker

Mara Koelker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mara Koelker has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Putnam Cole

    Brigham and Women’s Hospital

    4 shared publications
  • Quoc-Dien Trinh

    Division of Urological Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, MA; Center for Surgery and Public Health, Harvard Medical School, Brigham and Women's Hospital, Boston, MA

    3 shared publications
  • Benjamin V. Stone

    Division of Urological Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, MA; Center for Surgery and Public Health, Harvard Medical School, Brigham and Women's Hospital, Boston, MA

    2 shared publications
  • Caroline M. Moore

    Department of Urology University College London Hospitals NHS Foundation Trust London UK

    2 shared publications
  • Dejan K. Filipas

    Department of Urology University Medical Center Hamburg‐Eppendorf Hamburg Germany

    2 shared publications
  • Kemal Tuncali

    Department of Radiology, Harvard Medical School, Brigham and Women's Hospital, Boston, MA

    2 shared publications

Latest Publications

  • Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer

    by Zhiyu Qian, Dejan K. Filipas, Mara Koelker, Benjamin V. Stone, Edoardo Beatrici, Muhieddine Labban, Kemal Tuncali, Stuart Lipsitz, Quoc-Dien Trinh, Alexander P. Cole


  • Racial differences in patient‐reported outcomes among men treated with radical prostatectomy for prostate cancer

    by Mara Koelker, Muhieddine Labban, Nicola Frego, Jamie Ye, Stuart R. Lipsitz, Harrison Taylor Hubbell, Maria Edelen, Grant Steele, Kevin Salinas, Christian P. Meyer, et al.

    Background: Real‐world data on racial differences in the side effects of radical prostatectomy on quality of life (QoL) are lacking. We aimed to evaluate differences in patient‐reported outcome measure (PROM) among non‐Hispanic Black (NHB) and non‐Hispanic White (NHW) men using the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC‐CP) questionnaire to measure health‐related QoL after radical prostatectomy.Methods: We retrospectively assessed prospectively collected PROMs using EPIC‐CP scores at a tertiary care center between 2015 and 2021 for men with prostate cancer undergoing radical prostatectomy. The primary endpoint was the overall QoL score for NHB and NHW men, with a total score of 60 and higher scores indicating worse QoL. An imputed mixed linear regression model was used to examine the effect of covariates on the change in overall QoL score following surgery. A pairwise comparison was used to estimate the mean QoL scores before surgery as well as up to 24 months after surgery.Results: Our cohort consisted of 2229 men who answered at least one EPIC‐CP questionnaire before or after surgery, of which 110 (4.94%) were NHB and 2119 (95.07%) were NHW men. The QoL scores differed for NHB and NHW at baseline (2.34, 95% confidence interval [CI] 0.36–4.31, p = 0.02), 3 months (4.36, 95% CI 2.29–6.42, p < 0.01), 6 months (3.26, 95% CI 1.10–5.43, p < 0.01), and 12 months after surgery (2.48, 95% CI 0.19–4.77, p = 0.03) with NHB having worse scores. There was no difference in QoL between NHB and NHW men 24 months after surgery.Conclusions: A significant difference in QoL between NHB and NHW men was reported before surgery, 3, 6, and 12 months after surgery, with NHB having worse QoL scores. However, there was no long‐term difference in reported QoL. Our findings inform strategies that can be implemented to mitigate racial differences in short‐term outcomes.


  • Racial Disparities in Prostate Cancer Screening: The Role of Shared Decision Making

    by Nicola Frego, Edoardo Beatrici, Muhieddine Labban, Benjamin V. Stone, Dejan K. Filipas, Mara Koelker, Giovanni Lughezzani, Nicolò M. Buffi, Nora Y. Osman, Stuart R. Lipsitz, et al.


  • Open Access

    Oncological validation and discriminative ability of pentafecta criteria after open radical cystectomy

    by Markus von Deimling, Michael Rink, Jakob Klemm, Mara Koelker, Frederik König, Philipp Gild, Maryam Khonsari, Tim A. Ludwig, Phillip Marks, Roland Dahlem, et al.

    Objectives: To validate the pentafecta criteria (PC) proposed by the PROMETRICS group for outcome reporting after radical cystectomy in an open radical cystectomy (ORC) cohort with long‐term follow‐up and to assess the discriminative ability of PC attainment for oncological endpoints. Patients and Methods: Between January 2009 and December 2017, 420 patients underwent ORC with pelvic lymph node dissection and urinary diversion for non‐metastatic bladder cancer. The PC were defined as reported by the PROMETRICS group. The primary endpoint was PC attainment, and oncological outcomes comprised further endpoints. We used uni‐ and multivariable logistic regression analysis to assess predictors of PC attainment. The discriminative ability of PC for overall mortality (OM), cancer‐specific mortality (CSM) and other‐cause mortality (OCM) was compared using Kaplan–Meier curves and cumulative incidence functions. After stratification by the number of PC attained, the association between PC attainment and the survival endpoints was tested on multivariable Cox regression and competing‐risks models. Results: A total of 108 patients (26%) fulfilled all PC, while 195 (46%), 77 (18%), 35 (8.3%) and five (1.2%) attained 4/5, 3/5, 2/5 and ≤1/5 PC, respectively. Increasing age‐adjusted Charlson comorbidity index (odds ratio [OR] 0.80, P = 0.015) and incontinent diversion (OR 0.38, P = 0.005) were independent predictors of PC non‐attainment. The median follow‐up was 73 months. PC attainment (≥4/5 vs 3/5 vs ≤2/5 PC attained) was used to stratify patients into groups at significantly different risk of death ( P < 0.001). A decreasing number of PC attained (P ≤ 0.005) but not for OCM (all P ≥ 0.2). Conclusions: The PC proposed by the PROMETRICS group represent accurate quality indicators for oncological outcome reporting after ORC for non‐metastatic bladder cancer and have a distinct discriminative ability to predict long‐term OM and CSM.


  • Open Access

    Contemporary Patterns of Local Ablative Therapies for Prostate Cancer at United States Cancer Centers: Results from a National Registry

    by Alexander Cole, Mara Koelker, Muhieddine Labban, Nicola Frego, Christian P. Meyer, Georg Salomon, Stuart Lipsitz, John Withington, Caroline Moore, Clare Tempany, et al.

    BACKGROUND: Local ablative therapies, a partial-gland treatment for localized prostate cancer (PCa), offers targeted cancer treatment while minimizing side-effects. We aim to describe national-level patterns in its use for localized PCa in the United States (U.S.).METHODS:We retrospectively interrogated the hospital-based National Cancer Database (NCDB) for men with clinically localized PCa from 2010-2017. The main outcome was receipt of local tumor ablation with either cryo or laser-ablation, and other focal therapy including high-intensity focused ultrasound (HIFU). Patient level, hospital level, and demographic variables were collected. A mixed effects logistic regression analysis was utilized to identify covariates and predictors on the patient- and hospital-level. RESULTS: Overall, 11 278 patients received ablative therapy. Cryotherapy was performed in 8 883 (78.8%), laser ablation in 1 755 (15.6%), and other focal therapy (HIFU) in 640 (5.7%) cases. On the patient-level, intermediate-risk PCa patients were more likely to be treated with ablative therapy (OR 1.05, 95% CI 1.00 – 1.11, p=0.05) than low-risk PCa patients, as were men with Charlson Comorbidity Index >1 (OR 1.36, 95%CI 1.29 -1.43, pnd quartile, OR 1.23, 95% CI 1.12-1.35, pCONCLUSIONS: In this study, we report trends from 2010-2017, in utilization of local ablative therapies using a large national database of U.S. cancer centers. The technique is more commonly used in older men with comorbidities. The financial aspects of ablative therapy need to be addressed to avoid inequity in access to care.